結核病治療市場、機會、成長動力、產業趨勢分析與預測，2024-2032

由於潛伏性結核病 (TB) 病例盛行率不斷上升，結核病治療市場預計在 2024 年至 2032 年期間複合年成長率為 4.1%。據 NCBI 稱，目前世界上大約 25% 的人口感染了潛伏的結核分枝桿菌。據估計，世界上近四分之一的人口感染了潛伏性結核病，因此迫切需要有效的治療解決方案來防止進展為活動性結核病。這推動了對創新治療的需求，這些治療旨在在潛在感染活躍之前瞄準並根除它們。

人們越來越重視合併治療以提高治療效果。合併治療對於治療多重抗藥性 (MDR) 和廣泛抗藥性 (XDR) 結核病尤其重要，而單一藥物治療往往達不到這些要求。最近的發展催生了針對結核病感染多個方面的新藥物組合，減少了抗藥性的可能性並改善了患者的整體治療結果。這些合併治療方案縮短了治療時間，增強了藥物有效性，並提高了患者的依從性。

結核病治療產業根據疾病類型、治療方法、給藥途徑、劑型、配銷通路和地區進行分類。

到 2032 年，潛伏性結核病部分將迅速成長，因為在這個階段，細菌不活躍，不會引起症狀，但可以在以後重新激活，這對公共衛生提出了重大挑戰。潛伏結核病病例的增加推動了對新的和改進的治療方案的需求，以有效防止疾病的進展。藥物開發的最新進展導致了專門針對潛伏性結核病的新型治療藥物和聯合療法的推出。

由於藥物吸收快、治療效果立竿見影以及對劑量的精確控制，到 2032 年，腸外給藥領域將獲得相當大的牽引力。由於需要更有效和可靠的治療選擇，特別是對於多重抗藥性（MDR）和廣泛抗藥性（XDR）結核病病例，結核病治療中對腸外給藥的關注日益增加。腸外製劑和給藥系統的最新創新提高了藥物穩定性，提高了患者便利性，並最大限度地減少了副作用。

在結核病研究資金增加、宣傳活動提高以及先進醫療保健政策實施的推動下，歐洲結核病治療產業規模將在 2024 年至 2032 年快速成長。該地區各國對創新結核病療法和改進診斷工具以有效對抗疾病的需求不斷成長。強大的醫療保健基礎設施支持新治療方式和藥物傳輸系統的廣泛採用，將促進歐洲結核病治療市場的成長。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 結核病患率上升
    • 加大醫療基礎建設投資
    • 研究和開發活動的增加
    • 意識和舉措不斷增強
  • 產業陷阱與挑戰
    • 治療費用高
• 成長潛力分析
• 監管環境
• 報銷場景
• 技術景觀
• 未來市場趨勢
• 管道分析
• 差距分析
• 波特的分析
• PESTEL分析

第 4 章：競爭格局

• 介紹
• 公司矩陣分析
• 供應商矩陣分析
• 競爭定位矩陣
• 戰略儀表板

第 5 章：市場估計與預測：按疾病類型，2021 - 2032

• 主要趨勢
• 活動性結核病
• 潛伏性結核病

第 6 章：市場估計與預測：按療法分類，2021 - 2032 年

• 主要趨勢
• 一線治療
• 二線治療

第 7 章：市場估計與預測：按管理途徑，2021 - 2032 年

• 主要趨勢
• 口服
• 注射用
• 其他給藥途徑

第 8 章：市場估計與預測：按劑型，2021 - 2032

• 主要趨勢
• 平板電腦
• 膠囊
• 注射
• 其他劑型

第 9 章：市場估計與預測：按配銷通路，2021 - 2032

• 主要趨勢
• 醫院藥房
• 零售藥局
• 網路藥局

第 10 章：市場估計與預測：按地區分類，2021 - 2032 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙
  • 荷蘭
  • 歐洲其他地區
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
  • 亞太地區其他地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地區
• 中東和非洲
  • 沙烏地阿拉伯
  • 南非
  • 阿拉伯聯合大公國
  • 中東和非洲其他地區

第 11 章：公司簡介

• Aventis Pharmaceuticals Limited
• Bayer Health Care
• Eli Lilly And Company
• Johnson and Johnson Services; Inc.
• Lupin
• Macleods Pharmaceuticals Ltd.
• Mylan N.V.
• Otsuka Pharmaceutical Co., Ltd.
• Pfizer Inc.
• Sanofi.

The Tuberculosis Therapeutics Market is poised to register a 4.1% CAGR during 2024-2032, driven by the increasing prevalence of latent tuberculosis (TB) cases. According to NCBI, approximately 25% of the world's population is currently infected with Mycobacterium tuberculosis in a latent form. With nearly one-quarter of the world's population estimated to be infected with latent TB, there is an urgent need for effective therapeutic solutions to prevent the progression to active TB. This is pushing the demand for innovative treatments designed to target and eradicate latent infections before they become active.

There is a growing emphasis on combination therapy to enhance treatment outcomes. Combination therapy is particularly significant for treating multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB, where single-drug therapies often fall short. Recent developments have led to new drug combinations that target multiple aspects of TB infection, reducing the likelihood of resistance and improving overall patient outcomes. These combination regimens shorten treatment duration, enhance drug effectiveness, and improve patient adherence.

The tuberculosis therapeutics industry is classified based on disease type, therapy, route of administration, dosage form, distribution channel, and region.

The latent tuberculosis segment will grow rapidly through 2032, as it is a stage where the bacteria are inactive and not causing symptoms but can reactivate later, which presents a significant challenge for public health. The rise in latent TB cases is driving the demand for new and improved treatment regimens that can effectively prevent the progression of the disease. Recent advancements in drug development have led to the introduction of novel therapeutic agents and combination therapies specifically targeting latent TB.

The parenteral administration segment will witness decent traction through 2032, owing to rapid drug absorption, immediate therapeutic effects, and precise control over dosage. The increasing focus on parenteral administration in TB therapeutics is driven by the need for more effective and reliable treatment options, especially for multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB cases. Recent innovations in parenteral formulations and delivery systems have improved drug stability, enhanced patient convenience, and minimized side effects.

Europe tuberculosis therapeutics industry size will grow rapidly over 2024-2032, driven by increased funding for TB research, heightened awareness campaigns, and the implementation of advanced healthcare policies. Countries within the region are experiencing a growing demand for innovative TB therapies and improved diagnostic tools to combat the disease effectively. A robust healthcare infrastructure, which supports the widespread adoption of new therapeutic modalities and drug delivery systems, will augment the growth of the TB therapeutics market in Europe.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of Tuberculosis
    • 3.2.1.2 Increasing investment for healthcare infrastructure
    • 3.2.1.3 Rise in research and development activities
    • 3.2.1.4 Growing awareness and initiatives
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of treatment
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Reimbursement scenario
• 3.6 Technological landscape
• 3.7 Future market trends
• 3.8 Pipeline analysis
• 3.9 Gap analysis
• 3.10 Porter's analysis
• 3.11 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Vendor matrix analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Disease Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Active TB
• 5.3 Latent TB

Chapter 6 Market Estimates and Forecast, By Therapy, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 First-line therapy
• 6.3 Second-line therapy

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Parenteral
• 7.4 Other route of administration

Chapter 8 Market Estimates and Forecast, By Dosage Form, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Tablets
• 8.3 Capsules
• 8.4 Injection
• 8.5 Other dosage forms

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Hospital pharmacies
• 9.3 Retail pharmacies
• 9.4 Online pharmacies

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Italy
  • 10.3.5 Spain
  • 10.3.6 Netherlands
  • 10.3.7 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
  • 10.4.6 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
  • 10.5.4 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 South Africa
  • 10.6.3 UAE
  • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 Aventis Pharmaceuticals Limited
• 11.2 Bayer Health Care
• 11.3 Eli Lilly And Company
• 11.4 Johnson and Johnson Services; Inc.
• 11.5 Lupin
• 11.6 Macleods Pharmaceuticals Ltd.
• 11.7 Mylan N.V.
• 11.8 Otsuka Pharmaceutical Co., Ltd.
• 11.9 Pfizer Inc.
• 11.10 Sanofi.